Provided by Tiger Fintech (Singapore) Pte. Ltd.

PepGen Inc.

2.40
+0.14506.44%
Post-market: 2.35-0.0450-1.88%19:52 EDT
Volume:229.47K
Turnover:539.22K
Market Cap:78.30M
PE:-0.84
High:2.40
Open:2.39
Low:2.20
Close:2.25
Loading ...

Company Profile

Company Name:
PepGen Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
81
Office Location:
321 Harrison Avenue,8th Floor,Boston,Massachusetts,United States
Zip Code:
02118
Fax:
- -
Introduction:
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Directors

Name
Position
James McArthur
President, Chief Executive Officer and Director
Christopher Ashton
Director
Heidi Henson
Director
Joshua Resnick
Director
Laurie B. Keating
Director

Shareholders

Name
Position
James McArthur
President, Chief Executive Officer and Director
Michelle L. Mellion
Senior Vice President, Clinical Development
Niels Svenstrup
Senior Vice President, Chemistry, Manufacturing and Control
Noel Donnelly
Chief Financial Officer
Sonia Bracegirdle
Senior Vice President, Strategy and Operations
Jaya Goyal
Executive Vice President, Research and Preclinical Development